Poultry live attenuated vaccines are a type of vaccine used in the poultry industry to protect birds from various infectious diseases.

The global Poultry Live Attenuated Vaccine market size is projected to grow from US$ 2088.6 million in 2023 to US$ 2606.6 million in 2030; it is expected to grow at a CAGR of 3.2% from 2024 to 2030.

This Insight Report provides a comprehensive analysis of the global Poultry Live Attenuated Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

• Segmentation by type
• NDV
• Marek ' s Disease
• IBD
• Infectious Bronchitis
• Influenza
• Other

• Segmentation by application
• Chicken
• Other Poultry

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil

• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia

• Europe
• Germany
• France
• UK
• Italy
• Russia

• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration:

• MERCK
• Boehringer Ingelheim
• CEVA
• ZOETIS
• Vaxxinova
• ELANCO
• QYH BIOTECH
• PULIKE
• PHIBRO ANIMAL HEALTH CORPORATION
• HARBIN PHARMACEUTICAL GROUP
• MEVAC
• VENKY’S
• Dechra

Key Questions Addressed in this Report

• What is the 10-year outlook for the global Poultry Live Attenuated Vaccine market?
• What factors are driving Poultry Live Attenuated Vaccine market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Poultry Live Attenuated Vaccine market opportunities vary by end market size?
• How does Poultry Live Attenuated Vaccine break out type, application?